中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

109 records (took 0.117 seconds)

    Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
    28.
    发明申请
    Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors 审中-公开
    分类，诊断，分层和治疗癌症患者及其肿瘤的方法

    公开(公告)号：US20060040302A1

    公开(公告)日：2006-02-23

    申请号：US11200822

    申请日：2005-08-10

    Applicant: David Botstein ,  Patrick Brown ,  Charles Perou ,  Brian Ring ,  Douglas Ross ,  Rob Seitz ,  Jan van de Rijn

    Inventor： David Botstein ,  Patrick Brown ,  Charles Perou ,  Brian Ring ,  Douglas Ross ,  Rob Seitz ,  Jan van de Rijn

    IPC: C12Q1/68 ,  G01N33/574

    CPC classification number: C07K14/4748 ,  A61K38/00 ,  C07K16/18

    Abstract: The invention provides a variety of reagents for use in the diagnosis and management of cancer, particularly breast cancer. cDNA microarray technology was used to identify genes whose expression profile across a large group of tumor samples correlates with that of cytokeratin 5 and cytokeratin 17, markers for basal cells of the normal mammary lactation gland. The invention demonstrates that tumors that express cytokeratin 5/6 and/or 17 have a poor prognosis relative to tumors overall. The invention provides basal marker genes and their expression products and uses of these genes for diagnosis of cancer and for identification of therapies for cancer. In particular, the invention provides basal marker genes including cadherin3, matrix metalloproteinase 14, and cadherin EGF LAG seven-pass G-type receptor 2. The invention provides antibodies to the polypeptides expressed by these genes and methods of use thereof.

    Abstract translation: 本发明提供用于诊断和治疗癌症，特别是乳腺癌的各种试剂。 cDNA微阵列技术用于鉴定跨越大量肿瘤样本的表达谱与细胞角蛋白5和细胞角蛋白17（正常乳腺泌乳腺基底细胞的标记）相关的基因。 本发明表明，表达细胞角蛋白5/6和/或17的肿瘤总体上相对于肿瘤的预后差。 本发明提供了基础标记基因及其表达产物和这些基因用于诊断癌症和用于鉴定癌症疗法的用途。 特别地，本发明提供了包括钙粘蛋白3，基质金属蛋白酶14和钙粘蛋白EGF LAG七通G型受体2的基础标记基因。本发明提供了由这些基因表达的多肽的抗体及其使用方法。

    Polypeptides sharing sequence identity with a fibroblast growth factor polypeptide and nucleic acids encoding the same
    30.
    发明申请
    Polypeptides sharing sequence identity with a fibroblast growth factor polypeptide and nucleic acids encoding the same 审中-公开
    多肽与成纤维细胞生长因子多肽和编码相同的核酸共享序列同一性

    公开(公告)号：US20050196842A1

    公开(公告)日：2005-09-08

    申请号：US10413537

    申请日：2003-04-11

    Applicant: David Botstein ,  Audrey Goddard ,  Austin Gurney ,  Kenneth Hillan ,  David Lawrence ,  Margaret Roy

    Inventor： David Botstein ,  Audrey Goddard ,  Austin Gurney ,  Kenneth Hillan ,  David Lawrence ,  Margaret Roy

    IPC: C07K14/50 ,  C07H21/04 ,  C12N15/09

    CPC classification number: C07K14/50 ,  C07K2317/24 ,  C07K2319/00

    Abstract: The present invention is directed to novel polypeptides having homology to the PR0533 protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis and/or autocrine signaling. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, and may act of predictors of the prognosis of tumor treatment. Furthermore, the compounds, compositions including antagonists and methods of the present invention are further expected to have therapeutic effect upon conditions characterized by FgF-19 modulation.

    Abstract translation: 本发明涉及与PR0533蛋白质和编码那些多肽的核酸分子具有同源性的新型多肽。 本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明多肽的嵌合多肽分子，与本发明的多肽结合的抗体，以及本发明多肽的制备方法 发明。 本发明涉及用于诊断和治疗哺乳动物包括人类的肿瘤细胞生长和增殖的组合物和方法。 本发明基于在肿瘤细胞基因组中扩增的基因的鉴定。 预期这种基因扩增与基因产物的过度表达有关，并且有助于肿瘤发生和/或自分泌信号传导。 因此，由扩增的基因编码的蛋白质被认为是某些癌症的诊断和/或治疗（包括预防）的有用靶标，并且可以作为肿瘤治疗预后的预测因子。 此外，进一步预期本发明的化合物，包括拮抗剂和方法的组合物对于以FgF-19调节为特征的病症具有治疗作用。

Patent Agency Ranking